Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

The ATM gene (mutated in the disease ataxia telangiectasia) activates the p53 tumor suppressor protein in response to DNA damage, explaining the higher incidence of cancer in AT patients.